Overview
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2022-06-30
2022-06-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
Evaluate the long-term safety of amifampridine phosphate in the symptomatic relief of antibody positive MuSK-MG.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Catalyst Pharmaceuticals, Inc.Treatments:
3,4-diaminopyridine
4-Aminopyridine
Amifampridine
Criteria
Inclusion Criteria:- Participated in the MSK-002 study
Exclusion Criteria:
- Epilepsy and currently on medication
- Clinically significant abnormalities in ECG, in the opinion of the Investigator